These videos are promotional content funded by Sobi. This website is intended exclusively for healthcare professionals, meaning physicians, pharmacists, nurses, and other persons qualified to prescribe or supply medicinal products within the European Union. It is not intended for members of the general public. If you are not a healthcare professional, please do not proceed. This website contains promotional material and educational resources relating to Sobi medicines.
Information is based on the Kineret Summary of Product Characteristics (SmPC) approved by the European Commission for use in the European Economic Area (EEA). SmPC/Prescribing information, product availability, and reimbursement conditions may vary by country. Before prescribing, always refer to locally approved SmPC and/or prescribing information. The SmPC approved for use in the EEA can be accessed here. Adverse Events Reporting Information, as well as further details, can be found at the bottom of this webpage.
The latest European Alliance of Associations for Rheumatology (EULAR)/Paediatric Rheumatology European Society (PReS) recommendations on Still’s disease bring important advances in diagnosis and management. Click here to explore the recommendations and what they mean for your practice.
Gain practical insights from Bas Vastert (Pediatric Rheumatologist and Immunologist) and Eugen Feist (Adult Rheumatologist and Immunologist), as they share expert perspectives and address key questions clinicians may face when implementing these recommendations in real-world settings.
What are the Typical Clinical Manifestations Observed in Patients with Still’s Disease?
Hear about the challenges of identifying Still’s disease in patients without arthritis, and the role of biomarkers, such as C-reactive protein and ferritin, in diagnosis.1-4
PP-32240
What is the Treat-to-Target Strategy for Managing Still’s Disease?
Learn about a treat-to-target strategy for Still’s disease: resolving fever and C-reactive protein within a week, improving symptoms by 1 month, and sustaining low disease activity by 3 months.2
PP-32240
Does a ‘Window of Opportunity’ Exist in the Treatment of Still’s Disease?
Hear the expert discuss the ‘window of opportunity’ in Still’s disease, where early treatment can prevent disease progression, and long–term immune system effects.2,5-9
PP-32241
How Have the New EULAR/PReS Recommendations Changed the Approach to Diagnosing and Managing Still’s Disease?
Listen to the expert outline the new EULAR/PReS recommendations for Still’s disease, focusing on drug-free remission, early complication recognition, and reduced glucocorticoid use.2
PP-32242
To listen to the full podcast episodes and explore other interesting podcasts click here, or to listen to further clips from this series, click here.
Speakers
Bas Vastert
Pediatric Rheumatologist and Immunologist, UMC Utrecht, the Netherlands
Eugen Feist
Adult Rheumatologist and Immunologist, Klinik fur Rheumatologie und Klinische lmmunologie, Helios Fachklinik Vogelsang-Gommern GmbH, Gommern, Germany
References
1. De Matteis A et al. Systemic juvenile idiopathic arthritis and adult-onset Still’s disease are the same disease: evidence from systematic reviews and meta-analyses informing the 2023 EULAR/PReS recommendations for the diagnosis and management of Still’s disease. Ann Rheum Dis. 2024;83(12):1748-1761.
2. Ilaris® (canakinumab) US PI. 2024. Available at: https://www.novartis.com/us-en/sites/novartis_us/files/ilaris.pdf. Last accessed: 4 June 2026.
3. Kumar S et al. Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA). Pediatr Rheumatol Online J. 2012;10(1):40.
4. Mehta B, Efthimiou P. Ferritin in adult-onset still’s disease: just a useful innocent bystander?. Int J Inflam. 2012;2012:298405.
5. Bindoli S et al. Adult-onset still’s disease (AOSD): advances in understanding pathophysiology, genetics and emerging treatment options. Drugs. 2024;84(3):257-74.
6. European Medicines Agency (EMA). Ilaris® (canakinumab) Summary of Product Characteristics. 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris. Last accessed: 4 June 2026.
7. European Medicines Agency (EMA). Kineret® (anakinra) Summary of Product Characteristics. 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/kineret. Last accessed: 4 June 2026.
8. European Medicines Agency (EMA). RoActemra® (tocilizumab) Summary of Product Characteristics. 2024. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra. Last accessed: 4 June 2026.
9. Kontzias A et al. Diagnosing and treating systemic juvenile idiopathic arthritis and adult-onset Still’s disease as part of the Still’s disease continuum. Mediterr J Rheumatol. 2024;35(Suppl 1):45-57.
CRP: C-reactive protein; EULAR: European Alliance of Associations for Rheumatology; PreS: Paediatric Rheumatology European Society.
The information on this website does not replace the full prescribing details for any product. Before making any treatment decisions, please consult the applicable Summary of Product Characteristics (“SmPC”) and all relevant prescribing information for your market. Please note that approved indications, dosing, availability, and reimbursement status for Sobi medicines may vary across EU member states. You should verify the regulatory status and approved conditions of use for any product in your own jurisdiction.
Patient safety is a priority for Sobi. We are committed to collecting, analysing, and reacting to any new information about the benefits and risks of our products. If you have information about a side effect, or suspected adverse reaction associated with any of our products, please let us know via [email protected].
Suspected adverse reactions should also be reported to your national health authority, as applicable according to national legislation.
Copyright: Sobi and Kineret are trademarks of Swedish Orphan Biovitrum, AB (publ) © 2026 Swedish Orphan Biovitrum AB (publ) – All rights reserved www.sobi.com
Job code & DOP: PP-32998 July 2026
